CRG-022 is under clinical development by CARGO Therapeutics and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CRG-022’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CRG-022 is under development for the treatment of pediatric, young and adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL), refractory or relapsed (r/r) Philadelphia chromosome positive acute lymphoblastic leukemia (Ph positive ALL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma and chronic lymphocytic leukemia (CLL). It is a second generation m971 mAb-derived chimeric antigen receptors (CARs) T-cells transduced with lentivirus targeting CD22. It is administered through intravenous route as an infusion. The therapeutic candidate is developed based on the chimeric antigen receptor (CAR) technology.
CARGO Therapeutics overview
CARGO Therapeutics (CARGO) is a clinical-stage biotechnology company that focuses on advancing curative cell therapies for cancer patients. The company is developing a pipeline of chimeric antigen receptor (CAR) T-cell (CAR T-cell) therapies for cancer. Its pipeline portfolio includes CRG-022 (CAR T) and CRG-023 (tri-specific CAR T with CD2 co-stimulation). CARGO is developing CRG-022 for the treatment of large B-cell lymphoma, chronic lymphocytic leukemia and pediatric B- acute lymphocytic leukemia; and CRG-023 for B-cell malignancies. CARGO Therapeutics is headquartered in San Mateo, California, the US.
For a complete picture of CRG-022’s drug-specific PTSR and LoA scores, buy the report here.